Zeng et al., "PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy
," BMC Nephrology, vol.
(DN) is a disease of multifactorial pathogenesis involving several pathways which ultimately progress to reduction of renal functions.1,2 Estimated figures show that around 10-30% of type I diabetes mellitus and 15-40% of type II diabetes mellitus patients suffer from DN.2 Activation of protein kinase C, increased production of advanced glycosylation end products (AGEs), and diacylglycerol synthesis are proposed as some of the triggers for progression of DN.
Market outlook (2019-2023) is Latest Research on Diabetic Nephropathy
Market Information: By Diagnosis (Urine Test, Blood Test), By Treatment (Medications, Kidney Dialysis, Transplant), By Indication (Diabetes 1, Diabetes 2), By End User (Hospital & Clinic, Surgical Centers) - Global Industry Outlook to 2023.
XORTX has two lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy
and polycystic kidney disease
Fervenza, M.D., Ph.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues randomly assigned 130 patients with membranous nephropathy
to receive either intravenous rituximab or oral cyclosporine.
Swedish pharmaceutical company Calliditas Therapeutics AB said on Friday that it plans to develop and commercialise its leading drug candidate Nefecon in Greater China and Singapore for the chronic autoimmune kidney disease IgA Nephropathy
(IgAN) under a license agreement with Everest Medicines II Limited.
[ClickPress, Tue Apr 16 2019] Radiation nephropathy
treatment and management market is majorly driven by increasing prevalence of kidney disorders and rising patient population suffering from hypertension.
is an example of IgA1 immune complex disease.
Nondiabetic renal diseases (NDRDs) have different clinicopathological features and prognosis from those of diabetic nephropathy
. Our study sought to analyze the clinical and pathological features of NDRDs, in different age groups through a cross-sectional study.
Antiphospholipid syndrome nephropathy
(APSN) was noted in 4 (26%) patients at time of the first renal biopsy and in 9 (60%) on repeat biopsies.
A trial reported in the Journal of the American College of Nutrition found improvement in glucose metabolism as well as a decrease in oxidative stress and advanced glycation end products (AGEs) among individuals with diabetic nephropathy
(kidney damage caused by diabetes) who received coenzyme Q10 (CoQ10) compared to those who received a placebo.
Granular mesangial deposits of immunoglobulin (Ig)A (2C) and C3 (2+) were noted on immunofluorescence, along with rare mesangial deposits with paramesangial extension on electron microscopy, suggestive of IgA nephropathy
. IgG, IgM, fibrinogen, albumin, C3, C1q, C4, and kappa and lambda immunofluorescence stains were negative, but the average membrane thickness was 238.36 nm, which is consistent with a diagnosis of thin basement membrane nephropathy
Objective: To evaluate the incidence of contrast-induced nephropathy
(CIN) and its contributing factors after cardiac catheterization in type II diabetic patients.
Summary: Early diagnosis is critical to avoid the severe, often irreversible, complications of diabetic nephropathy